Influenza Clinical Trial
— FOCUSOfficial title:
Randomised, Open-label, Multi-Centre, Phase IV Study Assessing the Effect of Oseltamivir Treatment on Cognitive Function in Subjects With Confirmed Influenza Virus Infection
Verified date | September 2012 |
Source | Trial Management Group Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
This study has been designed to determine if subjects treated with oseltamivir in addition to standard of care treatment for influenza demonstrate a greater improvement in attention / working memory / processing speed / mood as compared to subjects receiving standard of care alone. The cognitive tests employed are objective measures developed and administered online by HeadMinder Inc.
Status | Completed |
Enrollment | 122 |
Est. completion date | April 2012 |
Est. primary completion date | April 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: 1. Adult men and women, 18 - 65 years of age (inclusive) 2. Indicative symptoms/signs of uncomplicated acute illness due to influenza infection (A or B strains) that started within a maximum of 2 days prior to Visit 1 as per the Tamiflu® Canadian product label. Signs and symptoms may include the following: - Fever - Respiratory symptoms (cough, coryza, sore throat, rhinitis) - Constitutional symptoms (headache, malaise, myalgia, sweats and/or chills, fatigue) 3. Positive rapid antigen test for influenza (A or B strains) at Visit 1 4. Negative urine pregnancy test at Visit 1 for women of childbearing potential; women of childbearing potential who are sexually active must agree to use a suitable form of contraception during the study. Acceptable birth control measures include: hysterectomy, birth control pills, tubal ligation, intrauterine device, hormonal injections and implants, double barrier methods (such as a condom with a diaphragm or a condom with spermicide), and abstinence. Oral contraceptives must be in stable use for 2 or more cycles prior to screening. Intrauterine device (IUD) must be in use at least 30 days prior to study drug administration. Barrier methods must be in use at least 14 days prior to study drug administration. 5. Subjects must: - have daily access to a computer at home with: internet access (preferably high-speed for optimal performance but dial-up can be used as well); Microsoft operating system; Internet Explorer browser capability and an e-mail account. A Macintosh (Mac) computer cannot be used. - be capable of and willing to complete the required online assessments in English according to the protocol schedule - be willing to abstain from the use of an antiviral medication if they are randomised to the standard of care treatment arm - have provided written informed consent prior to the initiation of any study procedures Exclusion Criteria: 1. More than 2 days since the onset of influenza symptoms 2. Subjects who, in the Investigator's judgment, require treatment with an antiviral medication as per the Canadian "Clinical Recommendations for Patients Presenting with Respiratory Symptoms During the 2009 - 2010 Influenza Season" (see Appendix D) 3. Clinical suspicion of infection with a respiratory virus other than influenza 4. Any medical condition that is sufficiently severe or unstable such that the subject is considered to be at imminent risk of requiring hospitalisation 5. History of conditions that may potentially affect cognitive function during the study, such as underlying neurologic conditions, depression or depressive disorders (unless the condition and treatment have been stable for 3 months), seasonal affective disorder (SAD), or any other cognitive impairment or dementia 6. Intermittent use of sedative-hypnotics; subjects who have been taking a fixed dose of a sedative-hypnotic every day for a period of at least 30 days may be included provided that they continue the same regimen throughout the study. 7. Intermittent or chronic use of psychiatric medications (with the exception of antidepressants that have been stable for 3 months) or anti-epileptic drugs 8. Nursing home residents 9. Known allergy to oseltamivir phosphate or any of the inactive ingredients of Tamiflu® 10. Women who are pregnant, or planning to become pregnant, or who are lactating 11. Current alcohol or drug abuse or substance dependence 12. Participation in another clinical trial with an investigational drug within the last 30 days 13. Patients vaccinated for influenza within 6 months of study enrollment 14. In the Investigator's judgment, the subject will not be able to adhere to the protocol requirements or is not suitable for study participation for any reason |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Moran Medical Centre | Collingwood | Ontario |
Canada | Dr. Kanani | Etobicoke | Ontario |
Canada | Dr. Herman | London | Ontario |
Canada | Milestone Research | London | Ontario |
Canada | SKDS Research Inc | Newmarket | Ontario |
Canada | Family First Medical Centre | Orleans | Ontario |
Canada | Steeple Hill Medical Centre | Pickering | Ontario |
Canada | Regina Medical Centre | Regina | Saskatchewan |
Canada | London Road Diagnostic Clinic and Medical Centre | Sarnia | Ontario |
Canada | Topsail Road Medical Clinic | St. John's | Newfoundland and Labrador |
Canada | DCTM Clinical Trials Group Ltd. | Strathroy | Ontario |
Canada | Dr. Gupta | Toronto | Ontario |
Canada | Dr. Collette | Vancouver | British Columbia |
Canada | Dr. Lai | Vancouver | British Columbia |
Canada | Devonshire Clinical Research Inc. | Woodstock | Ontario |
Lead Sponsor | Collaborator |
---|---|
Trial Management Group Inc. | Hoffmann-La Roche |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Mood (alertness, calmness and contentment) | Mood assessed using the Bond-Lader scales; factored for alertness, calmness and contentment. | 4 days | No |
Other | Influenza symptoms | Sum of the severity ratings (0 - 3) for 7 symptoms assessed daily. | 14 days | No |
Primary | Attention | Attention assessed using simple reaction time. Simple reaction time calculated as the mean of the following 2 sub-tests: Reaction Time Subtest Cued Reaction Time Subtest |
4 days | No |
Secondary | Working memory and processing speed | Working memory measured with the Dot Memory Test. Processing speed measured with Animal Number Decoding | 4 days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |